Fraunhofer Institute for Toxicology and Experimental Medicine

Fraunhofer researchers have succeeded in producing a bioresorbable membrane that is neither cytotoxic nor genotoxic.

Could getting rid of your cough, cold or fever be as simple as inhaling a spray? With RNA-based antiviral drugs, the answer could soon be yes.

What amount of PFAS is it safe to ingest? At Fraunhofer ITEM, we are investigating how PFAS impact people’s health. 

Through the establishment of a Division of Cardiovascular Research in 2021, the long-standing expertise in lung research is experiencing a synergetic further development of high clinical relevance. 

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

RNA-based therapeutics are a drug class with huge potential for medicine. Fraunhofer ITEM researchers develop novel drugs and methods for RNA-based therapeutic concepts.

Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.